Get the Stockscreener App
428.69
0.08%
-0.495
Madrigal Pharmaceuticals Inc stock is traded at $428.69, with a volume of 474.21K.
It is down -0.08% in the last 24 hours and down -3.22% over the past month.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
See More
Previous Close:
$429.18
Open:
$427.07
24h Volume:
474.21K
Relative Volume:
1.34
Market Cap:
$9.53B
Revenue:
-
Net Income/Loss:
$-518.67M
P/E Ratio:
-17.07
EPS:
-25.12
Net Cash Flow:
$-438.32M
1W Performance:
+3.10%
1M Performance:
-3.22%
6M Performance:
+25.83%
1Y Performance:
+96.90%
1-Day Range:
$393.61
$434.48
1-Week Range:
$393.61
$436.84
52-Week Range:
$213.71
$463.62
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Name
Madrigal Pharmaceuticals Inc
Sector
Industry
Phone
404-380-9263
Address
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Compare MDGL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
429.00 | 9.57B | 0 | -518.67M | -438.32M | -25.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
420.72 | 108.30B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
653.36 | 69.37B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
480.46 | 62.38B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
832.19 | 51.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
164.99 | 34.94B | 398.11M | -1.03B | -868.57M | -5.7032 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-25 | Initiated | Truist | Buy |
| Sep-04-25 | Resumed | H.C. Wainwright | Buy |
| Feb-28-25 | Upgrade | B. Riley Securities | Neutral → Buy |
| Feb-27-25 | Reiterated | H.C. Wainwright | Buy |
| Jun-28-24 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Apr-22-24 | Initiated | BofA Securities | Underperform |
| Mar-15-24 | Upgrade | B. Riley Securities | Sell → Neutral |
| Mar-06-24 | Initiated | Citigroup | Buy |
| Feb-26-24 | Downgrade | B. Riley Securities | Neutral → Sell |
| Dec-20-22 | Reiterated | Oppenheimer | Outperform |
| Dec-19-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-22 | Reiterated | Piper Sandler | Overweight |
| Dec-19-22 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jul-08-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Aug-06-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| May-20-21 | Resumed | Goldman | Buy |
| Nov-24-20 | Resumed | Evercore ISI | Outperform |
| Nov-06-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-05-20 | Initiated | BMO Capital Markets | Market Perform |
| May-05-20 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-20 | Initiated | Canaccord Genuity | Buy |
| Jan-09-20 | Upgrade | UBS | Neutral → Buy |
| Nov-07-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-19 | Initiated | Stifel | Hold |
| Jun-10-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Feb-28-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
| Jan-23-19 | Initiated | UBS | Neutral |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Dec-12-18 | Initiated | B. Riley FBR | Neutral |
| Nov-19-18 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Nov-16-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Sep-04-18 | Initiated | Citigroup | Buy |
| Aug-06-18 | Downgrade | Goldman | Buy → Neutral |
| Jun-28-18 | Initiated | Raymond James | Mkt Perform |
View All
Madrigal Pharmaceuticals Inc Stock (MDGL) Latest News
How Madrigal Pharmaceuticals Inc. stock reacts to global recession fearsMarket Activity Summary & Weekly High Return Stock Forecasts - newser.com
How to escape a deep drawdown in Madrigal Pharmaceuticals Inc.Weekly Gains Report & Community Verified Trade Alerts - newser.com
Is Madrigal Pharmaceuticals Inc. trending in predictive chart modelsEarnings Trend Report & Technical Buy Zone Confirmation - newser.com
Can Madrigal Pharmaceuticals Inc. stock hit record highs againPortfolio Performance Summary & Technical Confirmation Trade Alerts - newser.com
Madrigal Pharmaceuticals Experiences Evaluation Revision Amid Strong Market Performance - Markets Mojo
Madrigal (MDGL) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
Madrigal to Present New Data from the Company’s MASH Program at AASLD’s The Liver Meeting 2025 - The Manila Times
Madrigal Pharmaceuticals Inc. stock chart pattern explainedJuly 2025 Rallies & Real-Time Market Trend Scan - newser.com
Madrigal (NASDAQ: MDGL) to present cirrhosis and real-world Rezdiffra data at AASLD 2025 - Stock Titan
Will Madrigal Pharmaceuticals Inc. (YDO1) stock keep raising dividendsBond Market & Capital Efficiency Focused Ideas - newser.com
How strong is Madrigal Pharmaceuticals Inc. (YDO1) stock earnings growthMarket Performance Report & Expert Approved Momentum Trade Ideas - newser.com
Madrigal Pharmaceuticals Inc. stock trendline breakdownPortfolio Value Summary & Stepwise Trade Execution Plans - newser.com
Chart based exit strategy for Madrigal Pharmaceuticals Inc.Quarterly Investment Review & Precise Buy Zone Identification - newser.com
How forex fluctuations impact Madrigal Pharmaceuticals Inc. (YDO1) stockEarnings Trend Report & Daily Technical Stock Forecast Reports - newser.com
Statistical indicators supporting Madrigal Pharmaceuticals Inc.’s strengthTrade Signal Summary & Expert Approved Momentum Ideas - newser.com
How to integrate Madrigal Pharmaceuticals Inc. into portfolio analysis toolsMarket Risk Summary & Reliable Intraday Trade Alerts - newser.com
Will Madrigal Pharmaceuticals Inc. (YDO1) stock profit from AI boom2025 Earnings Impact & Daily Chart Pattern Signals - Fundação Cultural do Pará
Is it too late to sell Madrigal Pharmaceuticals Inc.Quarterly Risk Review & Low Drawdown Trading Strategies - newser.com
Madrigal Pharmaceuticals set to unveil Q3 2025 financial results on November 4 - Traders Union
Using RSI to spot recovery in Madrigal Pharmaceuticals Inc.July 2025 Review & Daily Technical Forecast Reports - newser.com
Is Madrigal Pharmaceuticals Inc a good long term investmentProtective Put Strategies & Unlock Free Weekly Portfolio Checkups - earlytimes.in
Madrigal Pharmaceuticals: Rezdiffra Commercialization Bode Well For Continued Growth MDGL - Seeking Alpha
Madrigal Pharmaceuticals Inc Stock (MDGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.06%
1.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):